FDA Determines Regulatory Review Period for INTRAROSA Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially announced its decision regarding the regulatory review period for INTRAROSA, a human drug product, following the submission of patent extension applications to the U.S. Patent and Trademark Office (USPTO).